Back to News
Market Impact: 0.35

Milestone Pharma Announces Approval Of Etripamil Nasal Spray In China; Triggers Milestone Payment

Source: Nasdaq

Regulation & LegislationHealthcare & BiotechProduct LaunchesCompany Fundamentals

Milestone Pharmaceuticals said China’s NMPA approved etripamil nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults. The approval is described as the first regulatory authorization for e... (ongoing from article text), a meaningful milestone that supports commercialization prospects in the China market.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

moderately positive

Sentiment Score

0.55

Ticker Sentiment

MIST0.75

More News

From AllMind Research

Browse all research